Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.Eur Urol [Internet]. 2011; 60: 742-750
- OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.Eur Urol. 2013; 64: 249-256
- Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action.Eur Urol. 2012; 61: 1178-1184
- Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study.Neurourol Urodyn. 2016; 35: 717-723
- Less is more—a pilot study evaluating one to three intradetrusor sites for injection of onabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.Neurourol Urodyn. 2017 Apr; 36: 1104-1107
- BotulinumtoxinA.Eur Urol Suppl. 2007; 6: 245
- Efficay and safety of two administration modes.Neurourol Urodyn. 2017; 36: 457-462
- Botulinum toxin a for the treatment of overactive bladder.Toxins (Basel). 2016; 8: 1-12
- OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.Int J Clin Pract. 2014; 68: 1246-1256
- Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.Urology. 2008; 72: 803-807
- Adaptación cultural al Español y validación psicométrica de la Escala de Beneficio del Tratamiento (Treatment Benefit Scale -TBS) en el tratamiento sintomático de la vejiga hiperactiva.Med Clin (Barc). 2013; 140: 6-13
- The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women.Neurourol Urodyn. 2015; 34: 128-132
- Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment.J Urol. 2016; 196: 801-808
- Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-a prospective randomized study to compare 30 vs 10 injections sites.Neururol Urodyn. 2005; 4-6: 547-548
- Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study.J Urol. 2016; 196: 791-800
- An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.Eur Urol. 2014 May; 65: 981-990
- Onabotulinumtoxina injections for idiopathic and neurogenic overactive bladder: discontinuation rates and reasons for treatment disruption in two Spanish hospitals.Neurourol Urodyn. 2015; 34: S111
- Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.Urology. 2013; 81: 491-497
Statement of ethics: The protocol study was approved by the Ethical Committee of the hospital The Spanish Medicines Agency (AEMPS) has classified this study as prospective follow-up post authorization study with code MEM-ONA-2018-01 Informed consent was signed by all the patients included in the study.
Funding sources: None.
Disclosure statement: Author Martínez-Cuenca has received a speaker honorarium from Astellas, and payment for research from Ipsen and Astellas.
Author Arlandis has received a speaker honorarium from Astellas, Boston and Neomedic, and payment for research from Ipsen and Astellas.
The others authors declare that they have no conflict of interest.